Mesoblast Reports Strong Ryoncil® Sales Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy MESO?
Source: Newsfilter
- Strong Sales Performance: Mesoblast reported net sales of $30.3 million for Ryoncil® (remestemcel-L-rknd) for the quarter ending March 31, 2026, with robust sales in February and March offsetting January's seasonal downturn, indicating sustained market demand for the product.
- Annual Revenue Approaching $100 Million: Since its launch, Ryoncil® has generated nearly $100 million in its first year, significantly strengthening Mesoblast's balance sheet and providing funding for label extensions and late-stage blockbuster programs, underscoring the company's leadership in cellular therapies.
- FDA-Approved Innovative Therapy: Ryoncil® is the first FDA-approved mesenchymal stromal cell product specifically for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD), giving the company a unique competitive edge in the market.
- Future Strategic Planning: Mesoblast will host its inaugural R&D Day on April 8, 2026, in New York, where it will outline the growth strategy for Ryoncil® and its robust late-stage product pipeline, further solidifying its position in the cellular therapy market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.460
Low
35.00
Averages
35.00
High
35.00
Current: 16.460
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesoblast Acquires Exclusive CAR Technology License
- Technology License Acquisition: Mesoblast has acquired an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic through the purchase of a startup, which is expected to significantly enhance the efficacy of its products, particularly in treating ulcerative colitis and Crohn's disease.
- Equity Financing: The acquisition was financed through the issuance of ASX ordinary shares, demonstrating the company's flexibility in capital operations while providing funding support for future technology development, thereby boosting market confidence.
- Enhanced Product Efficacy: Mesoblast indicated that the new CAR technology will improve the effectiveness of its mesenchymal lineage stromal cell (MSC) therapies, potentially offering stronger treatment outcomes for patients and enhancing the company's competitive position in the market.
- Support for Technological Advancement: As part of the deal, Mesoblast is committed to providing in-kind support to further advance the CAR technology and resulting products, reflecting the company's emphasis on innovation and commitment to long-term strategic development.
See More
Mesoblast Acquires CAR Technology Platform for MSC Products
- Technology Acquisition: Mesoblast Limited announced the acquisition of worldwide licensing rights to CAR technology from Mayo Clinic, completing the transaction through the issuance of ASX ordinary shares, aiming to enhance the target specificity and immunomodulation of therapeutic MSC products to improve treatment outcomes for inflammatory and autoimmune diseases.
- Product Development Plans: The company plans to utilize CAR-MSC technology designed to express CD19 on their surface to induce remission in Lupus Nephritis and other B-cell autoimmune diseases, demonstrating its potential in treating complex conditions.
- Support and Collaboration: As part of the acquisition, Mayo Clinic will provide technical support to advance CAR-MSC technology, including the implementation of good manufacturing practice (GMP) activities to ensure product quality and compliance.
- Market Performance: Mesoblast's stock closed at $14.61 on Tuesday, down 0.61%, and further declined to $14.50 in after-hours trading, indicating a cautious market reaction to the acquisition.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast Limited announced the acquisition of an exclusive worldwide license for a chimeric antigen receptor (CAR) technology platform, aimed at enhancing the precision and effectiveness of its mesenchymal stem cell (MSC) products by improving target specificity and strengthening immunomodulatory and tissue regeneration properties.
- Integration Plans: The company plans to integrate engineered CAR constructs into its MSC platforms, which already include the first and only FDA-approved MSC product in the United States, thereby significantly improving targeted homing to inflamed tissue and increasing potency in treating tissue-specific inflammatory diseases.
- Intellectual Property Acquisition: Mesoblast obtained exclusive rights to CAR-MSC intellectual property developed at Mayo Clinic through the acquisition of a startup, further advancing the technology and reinforcing its competitive position in next-generation cell therapies.
- Collaborative Support: As part of the agreement, Mayo Clinic will provide in-kind support to further develop the platform and resulting products, including GMP manufacturing activities, ensuring Mesoblast's leading position in the cell therapy sector.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast has secured an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic, aimed at enhancing the target specificity and immunomodulatory properties of therapeutic mesenchymal stem cell (MSC) products, thereby boosting efficacy and competitive positioning in the market.
- Enhanced Product Efficacy: By incorporating CAR technology into MSCs, Mesoblast plans to significantly improve targeted homing to inflamed tissues, which is expected to provide more potent treatment options for ulcerative colitis and Crohn's disease, addressing the market's demand for effective therapies.
- Strategic Support from Mayo Clinic: Mayo Clinic will provide technical support, including GMP manufacturing activities, to ensure the successful implementation of the new technology and high-quality production of products, thereby accelerating the time to market and enhancing market trust.
- Sustaining Market Leadership: The CEO of Mesoblast stated that this technology acquisition aligns well with the company's strategy to extend its market leadership, which is expected to drive further development in the treatment of inflammatory diseases and enhance its influence in the global market.
See More
Mesoblast Receives FDA Approval for DMD Clinical Trial
- FDA Approval for Trial: Mesoblast announced FDA clearance to directly proceed with a clinical trial for Ryoncil® targeting 15,000 children with DMD in the U.S., marking a significant advancement in addressing this severe condition.
- Trial Design and Objectives: The trial will randomize 76 patients aged 5 to 9 years to receive either Ryoncil® or placebo, with the primary endpoint being time-to-stand at nine months, aiming to leverage anti-inflammatory mechanisms to slow disease progression in DMD.
- Strengthened Partnerships: Mesoblast has partnered with Parent Project Muscular Dystrophy and the Duchenne Registry to enhance patient identification and trial awareness, ensuring successful execution of the study and bolstering the company's influence in the DMD treatment landscape.
- Strategic Implications: As the first FDA-approved mesenchymal stem cell product, Ryoncil® showcases Mesoblast's leadership in cell therapy, expected to provide new treatment options for DMD patients and improve their quality of life.
See More
Mesoblast Unveils Strategy to Double Revenues as Ryoncil Approaches $100M Milestone
- Revenue Growth Target: Mesoblast aims to double its revenues through its Ryoncil® product, which is expected to approach the $100 million net revenue milestone since its launch last year, indicating strong market performance and potential commercial success.
- Clinical Trial Progress: The company announced that enrollment for its Phase 3 trial for chronic low back pain (CLBP) will close at the end of this month, marking a significant step in its ongoing efforts to develop new therapies that are expected to drive future revenue growth.
- Product Expansion Strategy: The label extension strategy for Ryoncil® in adult and pediatric rare diseases has received approval from the central institutional review board, which is anticipated to further broaden market coverage and enhance the company's competitiveness in niche markets.
- Technology Acquisition: Mesoblast has acquired a patented CAR technology platform developed at the Mayo Clinic, aimed at enhancing the precision of its proprietary MSC products, a strategic move that will bolster the company's R&D capabilities and drive future product innovation.
See More
Mesoblast Acquires Exclusive CAR Technology License
- Technology License Acquisition: Mesoblast has acquired an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic through the purchase of a startup, which is expected to significantly enhance the efficacy of its products, particularly in treating ulcerative colitis and Crohn's disease.
- Equity Financing: The acquisition was financed through the issuance of ASX ordinary shares, demonstrating the company's flexibility in capital operations while providing funding support for future technology development, thereby boosting market confidence.
- Enhanced Product Efficacy: Mesoblast indicated that the new CAR technology will improve the effectiveness of its mesenchymal lineage stromal cell (MSC) therapies, potentially offering stronger treatment outcomes for patients and enhancing the company's competitive position in the market.
- Support for Technological Advancement: As part of the deal, Mesoblast is committed to providing in-kind support to further advance the CAR technology and resulting products, reflecting the company's emphasis on innovation and commitment to long-term strategic development.
See More
Mesoblast Acquires CAR Technology Platform for MSC Products
- Technology Acquisition: Mesoblast Limited announced the acquisition of worldwide licensing rights to CAR technology from Mayo Clinic, completing the transaction through the issuance of ASX ordinary shares, aiming to enhance the target specificity and immunomodulation of therapeutic MSC products to improve treatment outcomes for inflammatory and autoimmune diseases.
- Product Development Plans: The company plans to utilize CAR-MSC technology designed to express CD19 on their surface to induce remission in Lupus Nephritis and other B-cell autoimmune diseases, demonstrating its potential in treating complex conditions.
- Support and Collaboration: As part of the acquisition, Mayo Clinic will provide technical support to advance CAR-MSC technology, including the implementation of good manufacturing practice (GMP) activities to ensure product quality and compliance.
- Market Performance: Mesoblast's stock closed at $14.61 on Tuesday, down 0.61%, and further declined to $14.50 in after-hours trading, indicating a cautious market reaction to the acquisition.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast Limited announced the acquisition of an exclusive worldwide license for a chimeric antigen receptor (CAR) technology platform, aimed at enhancing the precision and effectiveness of its mesenchymal stem cell (MSC) products by improving target specificity and strengthening immunomodulatory and tissue regeneration properties.
- Integration Plans: The company plans to integrate engineered CAR constructs into its MSC platforms, which already include the first and only FDA-approved MSC product in the United States, thereby significantly improving targeted homing to inflamed tissue and increasing potency in treating tissue-specific inflammatory diseases.
- Intellectual Property Acquisition: Mesoblast obtained exclusive rights to CAR-MSC intellectual property developed at Mayo Clinic through the acquisition of a startup, further advancing the technology and reinforcing its competitive position in next-generation cell therapies.
- Collaborative Support: As part of the agreement, Mayo Clinic will provide in-kind support to further develop the platform and resulting products, including GMP manufacturing activities, ensuring Mesoblast's leading position in the cell therapy sector.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast has secured an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic, aimed at enhancing the target specificity and immunomodulatory properties of therapeutic mesenchymal stem cell (MSC) products, thereby boosting efficacy and competitive positioning in the market.
- Enhanced Product Efficacy: By incorporating CAR technology into MSCs, Mesoblast plans to significantly improve targeted homing to inflamed tissues, which is expected to provide more potent treatment options for ulcerative colitis and Crohn's disease, addressing the market's demand for effective therapies.
- Strategic Support from Mayo Clinic: Mayo Clinic will provide technical support, including GMP manufacturing activities, to ensure the successful implementation of the new technology and high-quality production of products, thereby accelerating the time to market and enhancing market trust.
- Sustaining Market Leadership: The CEO of Mesoblast stated that this technology acquisition aligns well with the company's strategy to extend its market leadership, which is expected to drive further development in the treatment of inflammatory diseases and enhance its influence in the global market.
See More
Mesoblast Receives FDA Approval for DMD Clinical Trial
- FDA Approval for Trial: Mesoblast announced FDA clearance to directly proceed with a clinical trial for Ryoncil® targeting 15,000 children with DMD in the U.S., marking a significant advancement in addressing this severe condition.
- Trial Design and Objectives: The trial will randomize 76 patients aged 5 to 9 years to receive either Ryoncil® or placebo, with the primary endpoint being time-to-stand at nine months, aiming to leverage anti-inflammatory mechanisms to slow disease progression in DMD.
- Strengthened Partnerships: Mesoblast has partnered with Parent Project Muscular Dystrophy and the Duchenne Registry to enhance patient identification and trial awareness, ensuring successful execution of the study and bolstering the company's influence in the DMD treatment landscape.
- Strategic Implications: As the first FDA-approved mesenchymal stem cell product, Ryoncil® showcases Mesoblast's leadership in cell therapy, expected to provide new treatment options for DMD patients and improve their quality of life.
See More
Mesoblast Unveils Strategy to Double Revenues as Ryoncil Approaches $100M Milestone
- Revenue Growth Target: Mesoblast aims to double its revenues through its Ryoncil® product, which is expected to approach the $100 million net revenue milestone since its launch last year, indicating strong market performance and potential commercial success.
- Clinical Trial Progress: The company announced that enrollment for its Phase 3 trial for chronic low back pain (CLBP) will close at the end of this month, marking a significant step in its ongoing efforts to develop new therapies that are expected to drive future revenue growth.
- Product Expansion Strategy: The label extension strategy for Ryoncil® in adult and pediatric rare diseases has received approval from the central institutional review board, which is anticipated to further broaden market coverage and enhance the company's competitiveness in niche markets.
- Technology Acquisition: Mesoblast has acquired a patented CAR technology platform developed at the Mayo Clinic, aimed at enhancing the precision of its proprietary MSC products, a strategic move that will bolster the company's R&D capabilities and drive future product innovation.
See More
